Win for PCSK9 inhibitors - Alirocumab ODYSSEY OUTCOMES Trial Anjali Nimesh Nimesh7 April 2018 8:00 PM ISTResidual risk of an acute coronary event in a patient of known coronary artery disease remains high despite maximum evidence base preventive therapy....
Alirocumab reduces risk of recurrent MI in ACS patients: ODYSSEY trial Medha Baranwal Baranwal2 Dec 2018 7:28 PM ISTAdministration of alirocumab in patients with a history of an acute coronary syndrome (ACS) and already receiving high-intensity statin therapy,...
FDA approves new PCSK9 inhibitor to lower LDL Cholesterol and CVD risk Dr. Kamal Kant Kohli Kohli27 April 2019 12:01 PM ISTFDA has approved new PCSK9 inhibitor, alirocumab for lowering LDL Cholesterol and CVD risk.The U.S. Food and Drug Administration (FDA) has approved...
